View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 5, 2022

Quidel’s quarterly revenues more than double to $1bn in Q1 2022

In the same quarter a year ago, the company reported revenues of $375.3m.

US-based Quidel has posted total revenues of $1.002bn for the first quarter (Q1) of the year, which ended on 31 March. The figure more than doubled the $375.3m reported in the same quarter a year ago.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The company attributed the jump to the increase in sales of its rapid immunoassay products.

Quidel’s rapid immunoassay revenue totalled $892.8m in Q1, driven by sales of QuickVue At-Home OTC Covid-19 tests as well as Sofia Influenza + SARS and Sofia Influenza tests.

Gross profit in the quarter was $740m, compared to $302m in the corresponding three-month period of 2021.

Quidel’s net income also soared to $479.9m, or $11.31 per diluted share, in Q1 2022, from $178.1m, or $4.09 per diluted share, in Q1 2021.

The company spent around $26m in research and development during the quarter, around $3.1m more than the previous year quarter.

Quidel president and CEO Douglas Bryant said: “We had an extraordinary start to the year, achieving record revenue and profitability along with strong cash generation as we continued to execute against our growth roadmap.

“Our diverse suite of assays, increasing brand strength and growing installed base of Sofia analysers continue to propel our market expansion, broadening our post-pandemic opportunities. Once again, the entire Quidel team performed brilliantly, and we fired on all cylinders.”

Quidel focuses on manufacturing rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems.

The company is said to be the first to market a rapid SARS-CoV-2 antigen test in the US.

Last December, Quidel signed a deal to acquire Ortho Clinical Diagnostics for $6bn. The deal is slated to close in the first half of the year.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network